Data Insights

Rilogrotug by AVEO Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval

Rilogrotug is under clinical development by AVEO Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Rilogrotug in Metastatic Colorectal Cancer

Data Insights

Rilogrotug by AVEO Pharmaceuticals for Metastatic Pancreatic Cancer: Likelihood of Approval

Rilogrotug is under clinical development by AVEO Pharmaceuticals and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Rilogrotug in Metastatic Pancreatic Cancer

Data Insights

Tivozanib hydrochloride by AVEO Pharmaceuticals for Neuroendocrine Cancer: Likelihood of Approval

Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Neuroendocrine Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Neuroendocrine Cancer

Data Insights

Tivozanib hydrochloride by AVEO Pharmaceuticals for Soft Tissue Sarcoma: Likelihood of Approval

Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Soft Tissue Sarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Soft Tissue Sarcoma

Data Insights

Tivozanib hydrochloride by AVEO Pharmaceuticals for Gallbladder Cancer: Likelihood of Approval

Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Gallbladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Gallbladder Cancer

Data Insights

Tivozanib hydrochloride by AVEO Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval

Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Pancreatic Cancer

Data Insights

Tivozanib hydrochloride by AVEO Pharmaceuticals for Prostate Cancer: Likelihood of Approval

Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Prostate Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Prostate Cancer

Data Insights

Ficlatuzumab by AVEO Pharmaceuticals for Oropharyngeal Cancer: Likelihood of Approval

Ficlatuzumab is under clinical development by AVEO Pharmaceuticals and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ficlatuzumab in Oropharyngeal Cancer

Data Insights

Tivozanib hydrochloride by AVEO Pharmaceuticals for Vulvar Cancer: Likelihood of Approval

Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Vulvar Cancer. According to GlobalData,...

Data Insights

Tivozanib hydrochloride by AVEO Pharmaceuticals for Breast Cancer: Likelihood of Approval

Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData,...

Data Insights

Tivozanib hydrochloride by AVEO Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...